• Arrowhead Pharmaceuticals recently reported topline results from its global Phase 3 SHASTA-3 and SHASTA-4 trials, showing that plozasiran achieved large triglyceride reductions and significantly lowered acute pancreatitis events in patients with severe hypertriglyceridemia while maintaining a favorable safety profile.
• Because plozasiran is already approved as REDEMPLO for familial chylomicronemia syndrome, these data give Arrowhead a basis to seek label expansion into the broader severe hypertriglyceridemia population across multiple regions.
• We will now examine how plozasiran’s strong Phase 3 data in severe hypertriglyceridemia may reshape Arrowhead’s existing investment narrative.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead today, you need to believe its RNAi platform can convert late stage assets into durable, commercial products, with plozasiran as a central proof point. The SHASTA-3 and SHASTA-4 results directly support the near term sNDA catalyst for severe hypertriglyceridemia, while also reducing one of the biggest risks: clinical or regulatory disappointment for plozasiran. Key uncertainties now tilt more toward reimbursement, pricing, and execution than clinical efficacy.

Among recent announcements, the broad regulatory approvals of REDEMPLO for familial chylomicronemia syndrome in the US, EU, China, Australia, and Canada look especially relevant. They show that regulators across major markets have already reviewed plozasiran’s core safety and mechanism, which may be helpful context as Arrowhead prepares a supplemental filing for the larger severe hypertriglyceridemia population and moves toward key late 2026 decisions.

Yet while the data look encouraging, investors should also be aware that pricing pressure and stricter reimbursement decisions could still...

Arrowhead Pharmaceuticals' narrative projects $704.7 million revenue and $133.3 million earnings by 2029.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $89.08 fair value, in line with its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were modeling Arrowhead’s revenue falling about 15% a year and still valuing it at around US$378.6 million in 2029, so if you only focus on today’s strong SHASTA-3 and SHASTA-4 readout and the risk of tighter reimbursement, you might miss how sharply opinions differ and why it can be useful to weigh several competing views before deciding what this news really means.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth just $89.08!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 47 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.